223 related articles for article (PubMed ID: 2518608)
1. [Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benzonidazole and nifurtimox].
Andrade SG; Magalhães JB; Pontes AL
Rev Soc Bras Med Trop; 1989; 22(3):113-8. PubMed ID: 2518608
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.
Andrade SG; Magalhães JB; Pontes AL
Bull World Health Organ; 1985; 63(4):721-6. PubMed ID: 3936634
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole].
Ferreira Hde O
Rev Soc Bras Med Trop; 1990; 23(4):209-11. PubMed ID: 2133586
[TBL] [Abstract][Full Text] [Related]
4. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
5. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
[TBL] [Abstract][Full Text] [Related]
6. Reversibility of muscle and heart lesions in chronic, Trypanosoma cruzi infected mice after late trypanomicidal treatment.
Segura MA; Molina de Raspi E; Basombrio MA
Mem Inst Oswaldo Cruz; 1994; 89(2):213-6. PubMed ID: 7885247
[TBL] [Abstract][Full Text] [Related]
7. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
8. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution.
Fabbro DL; Streiger ML; Arias ED; Bizai ML; del Barco M; Amicone NA
Rev Soc Bras Med Trop; 2007; 40(1):1-10. PubMed ID: 17486245
[TBL] [Abstract][Full Text] [Related]
9. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].
Coura JR; de Abreu LL; Willcox HP; Petana W
Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337
[TBL] [Abstract][Full Text] [Related]
10. [Isoenzymatic pattern of Trypanosoma cruzi Y strain after specific chemotherapy].
Silva RC; Santiago CM; Pontes AL; Andrade SG
Mem Inst Oswaldo Cruz; 1989; 84(1):81-6. PubMed ID: 2108307
[TBL] [Abstract][Full Text] [Related]
11. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains.
Andrade SG; Rassi A; Magalhaes JB; Ferriolli Filho F; Luquetti AO
Trans R Soc Trop Med Hyg; 1992; 86(6):624-6. PubMed ID: 1287919
[TBL] [Abstract][Full Text] [Related]
12. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
13. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
Filardi LS; Brener Z
Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
[TBL] [Abstract][Full Text] [Related]
15. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
Murcia L; Carrilero B; Albajar Viñas P; Segovia M
Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
[No Abstract] [Full Text] [Related]
16. Biochemical behavior of Trypanosoma cruzi strains isolated from mice submitted to specific chemotherapy.
Marretto JP; Andrade SG
Rev Soc Bras Med Trop; 1994; 27(4):209-15. PubMed ID: 7855362
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase].
Silveira CA; Castillo E; Castro C
Rev Soc Bras Med Trop; 2000; 33(2):191-6. PubMed ID: 10881133
[TBL] [Abstract][Full Text] [Related]
18. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
[TBL] [Abstract][Full Text] [Related]
19. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
[TBL] [Abstract][Full Text] [Related]
20. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
